Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Interstitial assessment of aggressive prostate cancer by physio-chemical photoacoustics: an ex vivo study with intact human prostates.

Huang S, Qin Y, Chen Y, Pan J, Xu C, Wu D, Chao WY, Wei JT, Tomlins SA, Wang X, Brian Fowlkes J, Carson PL, Cheng Q, Xu G.

Med Phys. 2018 Jun 23. doi: 10.1002/mp.13061. [Epub ahead of print]

PMID:
29935081
2.

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Zhang Y, Pitchiaya S, Cieślik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng FY, Malik R, Chinnaiyan AM.

Nat Genet. 2018 Jun;50(6):814-824. doi: 10.1038/s41588-018-0120-1. Epub 2018 May 28.

PMID:
29808028
3.

Ileal conduit vs orthotopic neobladder: Which one offers the best health-related quality of life in patients undergoing radical cystectomy? A systematic review of literature and meta-analysis.

Ziouziou I, Irani J, Wei JT, Karmouni T, El Khader K, Koutani A, Iben Attya Andaloussi A.

Prog Urol. 2018 Apr;28(5):241-250. doi: 10.1016/j.purol.2018.02.001. Epub 2018 Mar 20.

PMID:
29571902
4.

Analysis of veterinary drug residue monitoring results for commercial livestock products in Taiwan between 2011 and 2015.

Lee HC, Chen CM, Wei JT, Chiu HY.

J Food Drug Anal. 2018 Apr;26(2):565-571. doi: 10.1016/j.jfda.2017.06.008. Epub 2017 Jul 8.

5.

Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, Sanda MG, Gelfond J, Thompson IM, Leach RJ, Liss MA.

Eur Urol Focus. 2018 Feb 5. pii: S2405-4569(18)30011-7. doi: 10.1016/j.euf.2018.01.010. [Epub ahead of print]

PMID:
29422418
6.

Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.

Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT.

BJU Int. 2018 Jul;122(1):50-58. doi: 10.1111/bju.14151. Epub 2018 Mar 8.

PMID:
29388388
7.

Histotripsy Treatment of Benign Prostatic Enlargement Using the Vortx Rx System: Initial Human Safety and Efficacy Outcomes.

Schuster TG, Wei JT, Hendlin K, Jahnke R, Roberts WW.

Urology. 2018 Apr;114:184-187. doi: 10.1016/j.urology.2017.12.033. Epub 2018 Jan 9.

PMID:
29330000
8.

Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies.

Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC.

J Urol. 2018 Jun;199(6):1488-1493. doi: 10.1016/j.juro.2017.12.058. Epub 2018 Jan 4.

PMID:
29307684
9.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
10.

Motor performance in Prader-Willi syndrome patients and its potential influence on caregiver's quality of life.

Chiu VJ, Tsai LP, Wei JT, Tzeng IS, Wu HC.

PeerJ. 2017 Dec 13;5:e4097. doi: 10.7717/peerj.4097. eCollection 2017.

11.

Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies.

Barnett CL, Auffenberg GB, Cheng Z, Yang F, Wang J, Wei JT, Miller DC, Montie JE, Mamawala M, Denton BT.

Cancer. 2018 Feb 15;124(4):698-705. doi: 10.1002/cncr.31101. Epub 2017 Nov 13.

PMID:
29131319
12.

Development and Validation of a Quantitative Measure of Adaptive Behaviors in Women With Pelvic Floor Disorders.

Wei JT, Dunn R, Nygaard I, Burgio K, Lukacz ES, Markland A, Wren PA, Brubaker L, Barber MD, Jelovsek JE, Spino C, Meikle S, Janz N; PFDN.

Female Pelvic Med Reconstr Surg. 2017 Jul/Aug;23(4):232-237. doi: 10.1097/SPV.0000000000000431.

13.

Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S.

JAMA Oncol. 2017 Aug 1;3(8):1085-1093. doi: 10.1001/jamaoncol.2017.0177.

PMID:
28520829
14.

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Michalski JM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):304-317. doi: 10.1016/j.ijrobp.2017.02.019. Epub 2017 Feb 22.

15.

Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.

Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT.

Med Decis Making. 2017 Oct;37(7):815-826. doi: 10.1177/0272989X17696996. Epub 2017 Mar 31.

PMID:
28363265
16.

AUA White Paper on Nonneurogenic Chronic Urinary Retention: Consensus Definition, Treatment Algorithm, and Outcome End Points.

Stoffel JT, Peterson AC, Sandhu JS, Suskind AM, Wei JT, Lightner DJ.

J Urol. 2017 Jul;198(1):153-160. doi: 10.1016/j.juro.2017.01.075. Epub 2017 Feb 3.

PMID:
28163030
17.

Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.

O'Malley PG, Nguyen DP, Al Hussein Al Awamlh B, Wu G, Thompson IM, Sanda M, Rubin M, Wei JT, Lee R, Christos P, Barbieri C, Scherr DS.

J Urol. 2017 Jul;198(1):42-49. doi: 10.1016/j.juro.2017.01.058. Epub 2017 Jan 20.

18.

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.

Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW.

J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1.

19.

Treatment Availability Influences Physicians' Portrayal of Robotic Surgery During Clinical Appointments.

Scherr KA, Fagerlin A, Wei JT, Williamson LD, Ubel PA.

Health Commun. 2017 Jan;32(1):119-125. Epub 2016 May 6.

20.

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.

BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.

21.

Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.

Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG; PROST-QA Consortium.

J Urol. 2017 Feb;197(2):376-384. doi: 10.1016/j.juro.2016.08.101. Epub 2016 Sep 2.

22.

A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19.

23.

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM Jr, Carroll P.

JAMA Oncol. 2016 Jul 1;2(7):882-9. doi: 10.1001/jamaoncol.2016.0097.

PMID:
27032035
24.

Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R.

J Urol. 2016 Aug;196(2):405-11. doi: 10.1016/j.juro.2016.01.120. Epub 2016 Feb 23.

PMID:
26920466
25.

[Research progress on biological activities of Olea europaea leaf extract].

Zheng J, Wei JT, Liu JF, Liu YW.

Zhongguo Zhong Yao Za Zhi. 2016 Feb;41(4):613-618. doi: 10.4268/cjcmm20160411. Review. Chinese.

PMID:
28871681
26.

Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.

Xu G, Davis MC, Siddiqui J, Tomlins SA, Huang S, Kunju LP, Wei JT, Wang X.

Biomed Opt Express. 2015 Nov 9;6(12):4781-9. doi: 10.1364/BOE.6.004781. eCollection 2015 Dec 1.

27.

Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.

Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R.

Med Oncol. 2015 Nov;32(11):249. doi: 10.1007/s12032-015-0693-9. Epub 2015 Oct 6.

PMID:
26442515
28.

Understanding Inpatient Cost Variation in Kidney Transplantation: Implications for Payment Reforms.

Ellimoottil C, Ye Z, Chakrabarti AK, Englesbe MJ, Miller DC, Wei JT, Mathur AK.

Urology. 2016 Jan;87:88-94. doi: 10.1016/j.urology.2015.05.037. Epub 2015 Sep 14.

PMID:
26383614
29.

Evaluation of point-of-care PRO assessment in clinic settings: integration, parallel-forms reliability, and patient acceptability of electronic QOL measures during clinic visits.

Sharma P, Dunn RL, Wei JT, Montie JE, Gilbert SM.

Qual Life Res. 2016 Mar;25(3):575-83. doi: 10.1007/s11136-015-1113-5. Epub 2015 Sep 15.

PMID:
26373852
30.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

31.

Interpositional Nerve Grafting of the Prostatic Plexus after Radical Prostatectomy.

Kung TA, Waljee JF, Curtin CM, Wei JT, Montie JE, Cederna PS.

Plast Reconstr Surg Glob Open. 2015 Aug 10;3(7):e452. doi: 10.1097/GOX.0000000000000422. eCollection 2015 Jul.

32.

Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.

Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17.

33.

Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.

Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA; PROSTQA Study Consortium.

Radiother Oncol. 2015 Aug;116(2):179-84. doi: 10.1016/j.radonc.2015.07.016. Epub 2015 Aug 11.

PMID:
26276528
34.

A Generalized Assessment of the Impact of Regionalization and Provider Learning on Patient Outcomes.

Zhang Y, Lee SY, Gilleskie DB, Sun Y, Padakandla A, Jacobs BL, Montgomery JS, Montie JE, Wei JT, Hollenbeck BK.

Med Decis Making. 2016 Nov;36(8):990-8. doi: 10.1177/0272989X15593282. Epub 2015 Jul 13.

PMID:
26169752
35.

Sexual Health Concerns Among Cancer Survivors: Testing a Novel Information-Need Measure Among Breast and Prostate Cancer Patients.

Crowley SA, Foley SM, Wittmann D, Jagielski CH, Dunn RL, Clark PM, Griggs JJ, Peterson C, Leonard M, An LC, Wei JT, Montie JE, Janz NK.

J Cancer Educ. 2016 Sep;31(3):588-94. doi: 10.1007/s13187-015-0865-5.

PMID:
26076657
36.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

37.

Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance--How Many Cores are Enough?

Pham KN, Porter CR, Odem-Davis K, Wolff EM, Jeldres C, Wei JT, Morgan TM.

J Urol. 2015 Sep;194(3):674-9. doi: 10.1016/j.juro.2015.04.109. Epub 2015 May 9.

PMID:
25963186
38.

Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW.

Eur Urol. 2015 Dec;68(6):1083-8. doi: 10.1016/j.eururo.2015.03.023. Epub 2015 Mar 25.

39.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, Siddiqui J, Mosquera JM, Rubin MA, Sanda MG.

J Urol. 2015 Jul;194(1):65-72. doi: 10.1016/j.juro.2015.01.091. Epub 2015 Jan 28.

40.

Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.

Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):677-82. doi: 10.1158/1055-9965.EPI-14-1224. Epub 2015 Jan 22.

41.

Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.

Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng FY, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, Palapattu GS, Mehra R.

Asian J Urol. 2015 Jan;2(1):53-58. doi: 10.1016/j.ajur.2015.04.007. Epub 2015 Apr 16.

42.

Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic.

Gilbert SM, Dunn RL, Wittmann D, Montgomery JS, Hollingsworth JM, Miller DC, Hollenbeck BK, Wei JT, Montie JE.

Cancer. 2015 May 1;121(9):1484-91. doi: 10.1002/cncr.29215. Epub 2014 Dec 23.

43.

Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium.

Urology. 2015 Jan;85(1):101-5. doi: 10.1016/j.urology.2014.08.044.

44.

Anticipating the impact of insurance expansion on inpatient urological surgery.

Ellimoottil C, Miller S, Wei JT, Miller DC.

Urol Pract. 2014 Sep;1(3):134-140.

45.

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15.

46.

RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.

Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY.

Lancet Oncol. 2014 Dec;15(13):1469-80. doi: 10.1016/S1470-2045(14)71113-1. Epub 2014 Nov 17.

47.

Urinary biomarkers for prostate cancer.

Wei JT.

Curr Opin Urol. 2015 Jan;25(1):77-82. doi: 10.1097/MOU.0000000000000133. Review.

48.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG.

J Clin Oncol. 2014 Dec 20;32(36):4066-72. doi: 10.1200/JCO.2013.52.8505. Epub 2014 Nov 10.

49.

Computational simulation and preparation of fluorescent magnetic molecularly imprinted silica nanospheres for ciprofloxacin or norfloxacin sensing.

Gao B, He XP, Jiang Y, Wei JT, Suo H, Zhao C.

J Sep Sci. 2014 Dec;37(24):3753-9. doi: 10.1002/jssc.201401014. Epub 2014 Nov 17.

PMID:
25311209
50.

Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.

He J, Sun X, Shi T, Schepmoes AA, Fillmore TL, Petyuk VA, Xie F, Zhao R, Gritsenko MA, Yang F, Kitabayashi N, Chae SS, Rubin MA, Siddiqui J, Wei JT, Chinnaiyan AM, Qian WJ, Smith RD, Kagan J, Srivastava S, Rodland KD, Liu T, Camp DG 2nd.

Mol Oncol. 2014 Oct;8(7):1169-80. doi: 10.1016/j.molonc.2014.02.004. Epub 2014 Feb 21.

Supplemental Content

Support Center